key: cord-0325728-fj3xnb7n
authors: Patel, Nikita Mayur; Collotta, Debora; Aimaretti, Eleonora; Alves, Gustavo Ferreira; Kröller, Sarah; Coldewey, Sina Maren; Collino, Massimo; Thiemermann, Christoph
title: Inhibition of the JAK/STAT pathway with baricitinib reduces the multiple organ dysfunction caused by hemorrhagic shock in rats
date: 2022-01-13
journal: bioRxiv
DOI: 10.1101/2022.01.13.476088
sha: c238d080bf9c27ddd7d7207bca0891c4bb9e8de5
doc_id: 325728
cord_uid: fj3xnb7n

Objective The aim of this study was to investigate (a) the effects of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway inhibitor (baricitinib) on the multiple organ dysfunction syndrome (MODS) in a rat model of hemorrhagic shock (HS) and (b) whether treatment with baricitinib attenuates the activation of JAK/STAT, NF-κB and NLRP3 caused by HS. Background Post-traumatic MODS, which is in part due to excessive systemic inflammation, is associated with high morbidity and mortality. The JAK/STAT pathway is a regulator of numerous growth factor and cytokine receptors and, hence, is considered a potential master regulator of many inflammatory signaling processes. However, its role in trauma-hemorrhage is unknown. Methods An acute HS rat model was performed to determine the effect of baricitinib on MODS. The activation of JAK/STAT, NF-κB and NLRP3 pathways were analyzed by western blotting in the kidney and liver. Results We demonstrate here for the first time that treatment with baricitinib (during resuscitation following severe hemorrhage) attenuates the organ injury and dysfunction and the activation of JAK/STAT, NF-κB and NLRP3 pathways caused by HS in the rat. Conclusions Our results point to a role of the JAK/STAT pathway in the pathophysiology of the organ injury and dysfunction caused by trauma/hemorrhage and indicate that JAK inhibitors, such as baricitinib, may be repurposed for the treatment of the MODS after trauma and/or hemorrhage.

Trauma is one of the major causes of mortality in those aged under 44 and the number of patients dying from trauma surpasses those from tuberculosis, malaria and HIV/AIDS combined 1 . Annually, there are approximately 6 million trauma-associated mortalities worldwide. Trauma-associated hemorrhage accounts for almost 40% of all trauma deaths 2 and is a significant driver of multiple organ dysfunction syndrome (MODS) 3 . There is good evidence that a) uncontrolled systemic inflammation secondary to the release of damage-associated molecular patterns (DAMPs) from substantial tissue damage and b) ischemiareperfusion injury contribute to the onset of MODS 4 . However, there are no specific pharmacological interventions clinically used to prevent the onset of HS-induced MODS.

Circulating pro-inflammatory mediators bind to cell-surface receptors and subsequently signal through activation of intracellular protein tyrosine kinases, including the Janus kinase (JAK) family. The JAK family is composed of JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2) and these isoforms interact with the signal transducer and activator of transcription (STAT) class of proteins 5 . JAK inhibitors affect the JAK-STAT protein interaction and disrupt the propagation of signals through the JAK/STAT pathway, thus modulating inflammatory signaling processes.

We have recently shown that JAK/STAT inhibition reduced both the diet-related metabolic derangements and the associated organ injury/dysfunction in a murine model of high-fat diet-induced type 2 diabetes 6 .

Specifically, treatment with baricitinib, a JAK1/JAK2 inhibitor, resulted in improvements of diet-induced myosteatosis, mesangial expansion and associated proteinuria in addition to reducing blood cytokine levels, renal dysfunction and skeletal muscle damage. 5 Driven by the COVID-19 pandemic, strategies focusing on drug repurposing which dampen the cytokine storm and pulmonary injury associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been examined. Recent investigations have shown that baricitinib, which is thought to possess antiviral properties through its affinity for adaptor-associated kinase-1 and the subsequent reduction in SARS- 

Original data were obtained under Gene Expression Omnibus (GEO) accession GSE36809, published by Xiao and colleagues 26 . RNA was extracted from whole blood leukocytes of severe blunt trauma patients (n = 167) over the course of 28 days and healthy controls (n = 37) and hybridized onto an HU133 Plus 2.0 GeneChip (Affymetrix) according to the manufacturer's recommendations. The dataset was reanalyzed for JAK2 and STAT3 gene expression. A further reanalysis was performed dividing the trauma patients into uncomplicated (n = 55) and complicated (n = 41) groups.

All animal procedures were approved by the Animal Welfare Ethics Review Board of Queen Mary University of London and by the Home Office (License number PC5F29685).

Male Wistar rats (Charles River Laboratories Ltd., Kent, UK) weighing 260-310 g were kept under standard laboratory conditions and received a chow diet and water ad libitum. Baricitinib (Insight Biotechnology, UK) was diluted in 5 % DMSO + 95 % Ringer's Lactate (vehicle) and rats were treated (i.p.) upon resuscitation. Further information about baricitinib can be found in the supplemental.

The acute hemorrhagic shock model was performed as previously described 27, 28 . Briefly, forty rats were anesthetized with sodium thiopentone (120 mg/kg i.p. initially and 10 mg/kg i.v. for maintenance as needed) 7 and randomized into four groups: Sham + vehicle (n = 10); Sham + baricitinib (1 mg/kg; n = 9), HS + vehicle (n = 11); HS + baricitinib (1 mg/kg; n = 10). Blood was withdrawn to achieve a fall in mean arterial pressure (MAP) to 35 ± 5 mmHg, which was maintained for 90 min. At 90 min after initiation of hemorrhage (or when 25% of the shed blood had to be reinjected to sustain MAP), resuscitation was performed. At 4 h post-resuscitation, blood was collected for the measurement of biomarkers of organ injury/dysfunction (MRC Harwell Institute, Oxfordshire, UK). Sham-operated rats were used as control and underwent identical surgical procedures, but without hemorrhage or resuscitation. Detailed description of the model can be found in the supplemental (Supplementary eFigure 1).

Semi-quantitative immunoblot analysis was carried out in liver and kidney tissue samples as previously described 27, 28 . Detailed description of the method can be found in the supplemental.

Renal sections (2 µm) were deparaffinized and hydrated as previously described 29 and stained for CD68.

Detailed description of the method can be found in the supplemental.

Periodic acid Schiff (PAS) staining of renal sections (2 µm) was performed using a PAS staining kit (Carl Roth, Karlsruhe, Germany). Histomorphological changes were evaluated at 20x magnification using a scoring system as previously described 29 . Images were taken using a KEYENCE BZ-X800 microscope and BZ-X800 viewer after performing white balance and auto exposure.

All data in text and figures are expressed as mean ± SEM of n observations, where n represents the number of animals/experiments/subjects studied. Measurements obtained from the patient groups and vehicle and baricitinib treated animal groups were analyzed by one-way/two-way ANOVA followed by Bonferroni's post-hoc test or Kruskal-Wallis test followed by Dunn's post-hoc test on GraphPad Prism 8.0 (GraphPad Software, Inc., La Jolla, CA, USA). The distribution of the data was verified by Shapiro-Wilk normality test, and the homogeneity of variances by Bartlett test. When necessary, values were transformed into logarithmic values to achieve normality and homogeneity of variances. P<0.05 was considered statistically significant.

Xiao and colleagues 26 compared genome-wide gene expression in leukocytes from trauma patients against matched healthy controls. We reanalyzed this dataset for JAK2 and STAT3 expression, as STAT3 is the most commonly stimulated downstream STAT following JAK2 activation. When compared to healthy controls, JAK2 expression was significantly elevated in patients with trauma at all time points (p<0.05; Figure 1A ). An initial peak was noted at Day 1 followed by a gradual decrease, however, JAK2 expression still remained elevated at Day 28 after trauma. Similarly, STAT3 expression was significantly increased at all time points (p<0.05; Figure 1B ) and an initial peak was noted at 12 h followed by a gradual decrease.

However, STAT3 expression also still remained elevated at Day 28 after trauma. When comparing trauma patients stratified into uncomplicated (recovery in <5 days) and complicated (recovery after 14 days, no recovery by Day 28 or death) groups, JAK2 expression was significantly higher on Days 4 and 7 (p<0.05; Figure 1C ) and STAT3 expression was significantly raised at 12 h (p<0.05; Figure 1D ) in complicated patients when compared to uncomplicated trauma patients. These data indicate that the JAK2/STAT3 pathway may play a role in the pathophysiology of trauma.

Here we explored whether pharmacological intervention with the JAK1/JAK2 inhibitor baricitinib attenuates the MODS associated with HS in rats. When compared to sham-operated rats, rats subjected to HS displayed significant increases in serum urea (p<0.05; Figure 2A ) and creatinine (p<0.05; Figure 2B ); indicating the development of renal dysfunction. When compared to sham-operated rats, vehicle treated HS-rats exhibited significant increases in ALT (p<0.05; Figure 2C ) and AST (p<0.05; Figure 2D ) indicating the development of hepatic injury, while the increases in amylase (p<0.05; Figure 2E ) and CK (p<0.05; Figure 2F ) denote pancreatic and neuromuscular injury, respectively. The significant increase in LDH (p<0.05; Figure 2F ) in vehicle treated HS-rats confirmed tissue injury. Treatment of HS-rats with baricitinib significantly attenuated the renal dysfunction, hepatic injury, pancreatic injury, neuromuscular injury and general tissue damage caused by HS as shown by the reduction in serum parameter values (all p<0.05;

Administration of baricitinib to sham-operated rats had no significant effect on any of the parameters measured (p>0.05; Figure 2 ).

Using western blot analysis, we examined whether HS leads to the activation of the JAK2/STAT3 pathway in the liver and kidney, given that treatment with baricitinib significantly attenuated HS-associated hepatic injury and renal dysfunction. When compared to sham-operated rats, vehicle treated HS-rats displayed significant increases in the phosphorylation of hepatic and renal Jak2 at Tyr 1007-1008 (p<0.05; Figures 3A-B) and Stat3 at Tyr 705 (p<0.05; Figures 3C-D) , indicating that the JAK2/STAT3 pathway is activated in the injured liver and kidneys. Treatment of HS-rats with baricitinib significantly abolished these increases in JAK2/STAT3 phosphorylation (p<0.05; Figures 3A-D) .

The effect of JAK/STAT inhibition on the activation of NF-κB were investigated in liver and kidney. When 

Having discovered that baricitinib significantly reduced NF-κB activation in the liver and kidney of HSrats, we next analyzed the potential involvement of the NLRP3 inflammasome complex. When compared to sham-operated rats, vehicle treated HS-rats exhibited significantly increased hepatic and renal expression 

Having shown that baricitinib significantly attenuated the HS-induced renal dysfunction, we investigated renal macrophage infiltration and tissue injury determined by CD68 and PAS staining, respectively. When compared to sham-operated rats, vehicle treated HS-rats exhibited a significantly increased expression of CD68 in the kidney (p<0.05; Figure 4A ). Treatment with baricitinib in HS-rats significantly reduced CD68 expression, indicating an attenuation of renal macrophage invasion (p<0.05; Figure 4A ). When compared to sham-operated rats, vehicle treated HS-rats displayed a significantly raised renal PAS score (p<0.05; Figure 4C ). Treatment with baricitinib in HS-rats reduced this rise in PAS score (albeit this change was not statistically significant), suggesting a tissue protective effect of baricitinib in the kidney ( Figure 4C ).

To investigate the effects of baricitinib on circulatory failure, MAP was measured from the completion of surgery to the termination of the experiment. Baseline MAP values were similar amongst all four groups.

Rats subjected to HS demonstrated a decline in MAP which was ameliorated by resuscitation, but MAP remained lower than that of sham-operated rats during resuscitation (at the equivalent time points, Figure   5 ). The MAP of baricitinib treated HS-rats was similar to those of vehicle treated HS-rats at the end of the resuscitation period ( Figure 5 ). Administration of baricitinib to sham-operated rats had no significant effect on MAP (p>0.05; Figure 5 ).

This study reports that inhibition of JAK/STAT activity attenuates the organ injury/dysfunction associated with HS (acute rat model; Figure 2 ). Having shown that JAK2 and STAT3 gene expression is significantly elevated in leukocytes of trauma patients (Figures 1A-B) and, most notably, that the expression of JAK2 and STAT3 is higher in trauma patients with a complicated recovery ( Figures 1C-D) , we used a reverse translational approach to investigate whether pharmacological intervention with the JAK1/JAK2 inhibitor baricitinib ameliorates the MODS associated with HS in a well-established rat model [30] [31] [32] .

Baricitinib inhibits JAK1 and JAK2 to an equal degree and is currently used in patients with inflammatory diseases, including rheumatoid arthritis and atopic dermatitis 33 . We report here for the first time that baricitinib significantly attenuated the renal dysfunction, hepatic injury, pancreatic injury and neuromuscular injury caused by HS (Figure 2) . Similarly, JAK inhibition lowers disease severity in animal models of ischemia-reperfusion injury 34 14 A synergistic interaction between STAT and NF-κB occur on many levels: these include physical interactions of the two molecules, cooperative binding at particular gene promoter subsets to induce target gene expression and cytokine feedback loops, whereby cytokines induced by STAT and NF-κB (e.g. can further prolong the activation of both molecules 47 . Trauma leads to increased nuclear translocation of NF-κB 27, 28, [30] [31] [32] . Inhibition of JAK2/STAT3 activity with baricitinib decreased NF-κB activation in both the liver and kidneys (Figure 3) . We also found a significant positive correlation between the activation of JAK2 and the phosphorylation of IκBα at Ser 32/36 and translocation of p65 (Supplementary eFigure 2) . This may suggest that blocking the activation of NF-κB contributes to the observed effects of baricitinib in HS.

Activation of NF-κB drives the production of multiple pro-and anti-inflammatory mediators including enzymes, cytokines and chemokines 48 . As part of a positive feedback loop, these mediators can activate NF-κB and its upstream signaling components, further amplifying and sustaining the inflammatory responses mediated by NF-κB which can lead to greater permeability of the endothelium, hypoperfused/hypoxic tissues, tissue injury and eventually MODS 49 .

The JAK/STAT pathway has also been shown to be linked to the NLRP3 inflammasome, with pharmacological inhibition of JAK reducing the expression and activation of NLRP3 inflammasome components 50, 51 . NLRP3 inflammasome activation drives the formation of IL-1β which plays a key role in the systemic inflammation and/or organ dysfunction associated with trauma 27,28 . Inhibition of JAK2/STAT3 activity with baricitinib decreased the assembly and successive activation of the NLRP3 inflammasome in the liver and kidneys (Figure 3) . We also discovered a significant positive correlation between JAK2 activation and the activation of NLRP3 and caspase 1 (Supplementary eFigure 2) . A recent phenotypic high-content, high-throughput screen identified targeting JAK to inhibit NLRP3 inflammasome activation 52 . This may suggest that blocking the activation of the NLRP3 inflammasome contributes to the observed protective effects of baricitinib in HS by reducing the pro-inflammatory effects of IL-1β and ensuing tissue inflammation.

The sterile inflammation caused by HS drives the recruitment of leukocytes to the tissues and is secondary to NF-κB and NLRP3 activation and their associated transcriptional regulation of pro-inflammatory cytokines [53] [54] [55] . Furthermore, leukocytes and endothelial cells express adhesion molecules, and this is regulated by NF-κB to facilitate leukocyte extravasation from the circulation to the site of damage 56 . It has been shown that experimental injury induces a transcriptomic shift in leukocytes 4 h post trauma and HS and several pathways related to innate immunity were upregulated; including those involved in myeloid leukocyte activation and differentiation 57 . We measured CD68 expression and PAS score in the kidney as markers of macrophage infiltration and overall tissue injury, respectively 58 

In conclusion, we report here for the first time that baricitinib reduces the organ injury/dysfunction caused by severe hemorrhage in the rat, highlighting a role of the JAK2/STAT3 pathway in disease pathogenesis.

Additionally, experimental trauma-hemorrhage results in a significant activation of the JAK2/STAT3 pathway in the liver and kidneys. Administration of baricitinib during resuscitation after major hemorrhage abolished the activation of JAK2/STAT3 as well as the activation of NF-κB and the NLRP3 inflammasome (liver and kidney); both of which are major drivers of local and systemic inflammation. Therefore, we propose that JAK inhibitors, such as baricitinib, may be repurposed to reduce the organ injury and inflammation caused by severe hemorrhage and resuscitation in patients with trauma. was measured from the completion of surgery to the termination of the experiment for vehicle and BAR (baricitinib) treated rats. Data are expressed as mean ± SEM of 9-11 animals per group. Statistical analysis was performed using two-way ANOVA followed by a Bonferroni's post-hoc test. *p<0.05 Sham + vehicle vs. HS + vehicle.

Injuries and Violence: The Facts

The acute management of trauma hemorrhage: A systematic review of randomized controlled trials

Postinjury multiple organ failure

The systemic immune response to trauma: An overview of pathophysiology and treatment. The Lancet

Jaks and STATs: Biological implications

Baricitinib counteracts metaflammation, thus protecting against diet-induced metabolic abnormalities in mice

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. The Lancet

Baricitinib restrains the immune dysregulation in patients with severe COVID-19

Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact

Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study

Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: An observational cohort study

Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallelgroup, placebo-controlled phase 3 trial. The Lancet Respiratory

Additional baricitinib loading dose improves clinical outcome in COVID-19

Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study. Reumatología Clínica

Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallelgroup, placebo-controlled phase 3 trial. The Lancet Respiratory Medicine

JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality

Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesh

Real-life effectiveness and safety of baricitinib as adjunctive to standard-of-care treatment in hospitalized patients with severe COVID-19. Open Forum Infectious Diseases

Overview | Baricitinib for treating moderate to severe atopic dermatitis | Guidance | NICE

Activation of JAK2/STAT pathway in cerebral cortex after experimental traumatic brain injury of rats

JAK/STAT pathway regulation of GABAA receptor expression after differing severities of experimental TBI

Hemorrhagic Shock Sensitized the Diaphragm to Ventilator-Induced Dysfunction through the Activation of IL-6/JAK/STAT Signaling-Mediated Autophagy in Rats

A genomic storm in critically injured humans

Inhibition of Bruton's tyrosine kinase activity attenuates trauma-induced multiple organ dysfunction in rats. bioRxiv

The inhibition of Macrophage Migration Inhibitory Factor by ISO-1 attenuates trauma-induced multi organ dysfunction in rats. medRxiv

Modeling hemolytic-uremic syndrome: In-depth characterization of distinct murine models reflecting different features of human disease

Resolvin D1 Attenuates the Organ Injury Associated With Experimental Hemorrhagic Shock

Artesunate protects against the organ injury and dysfunction induced by severe hemorrhage and resuscitation. Annals of Surgery

Novel Synthetic, Host-defense Peptide Protects Against Organ Injury/Dysfunction in a Rat Model of Severe Hemorrhagic Shock. Annals of Surgery

Blockage of JAK/STAT signalling attenuates renal ischaemiareperfusion injury in rat

Edaravone alleviates cell apoptosis and mitochondrial injury in ischemia-reperfusion-induced kidney injury via the JAK/STAT pathway

JAK/STAT signaling is associated with cardiac dysfunction during ischemia and reperfusion

Ischemic postconditioning during reperfusion attenuates intestinal injury and mucosal cell apoptosis by inhibiting JAK/STAT signaling activation

Blockade of Janus kinase-2 signaling ameliorates mouse liver damage due to ischemia and reperfusion

Dexmedetomidine protects against renal ischemia and reperfusion injury by inhibiting the JAK/STAT signaling activation

Inhibition of Janus kinase 2 and signal transduction and activator of transcription 3 protect against cecal ligation and puncture-induced multiple organ damage and mortality

JAK2 inhibition prevents innate immune responses and rescues animals from sepsis

Treatment of experimental Candida sepsis with a

Janus Kinase inhibitor controls inflammation and prolongs survival

Tofacitinib treatment aggravates Staphylococcus aureus septic arthritis, but attenuates sepsis and enterotoxin induced shock in mice

Tofacitinib Ameliorates Lipopolysaccharide-Induced Acute Kidney Injury by Blocking the JAK-STAT1/STAT3 Signaling Pathway

Effects of tyrphostins and genistein on the circulatory failure and organ dysfunction caused by endotoxin in the rat: A possible role for protein tyrosine kinase

Genome-wide association study of serum liver enzymes implicates diverse metabolic and liver pathology

NF-κB and STAT3 signaling pathways collaboratively link inflammation to cancer

The IKK/NF-kappa B pathway

NF-κB activation as a pathological mechanism of septic shock and inflammation

Janus Kinase Inhibition Ameliorates Ischemic Stroke Injury and Neuroinflammation Through Reducing NLRP3 Inflammasome Activation via JAK2/STAT3

Tofacitinib inhibits granulocyte-macrophage colonystimulating factor-induced NLRP3 inflammasome activation in human neutrophils

A phenotypic high-content, high-throughput screen identifies inhibitors of NLRP3 inflammasome activation

Transcriptional regulation of endothelial cell adhesion molecules: A dominant role for NF-κB

Transcriptional regulation of endothelial cell adhesion molecules: NF-κB and cytokine-inducible enhancers

Hepatic Nuclear Factor κB Regulates Neutrophil Recruitment to the Injured Brain

NF-κB in immunobiology

Hemorrhagic Shock Induces a Rapid Transcriptomic Shift of the Immune Balance in Leukocytes after Experimental Multiple Injury

CD68/macrosialin: not just a histochemical marker. Laboratory Investigation

Clinical Efficacy and Adverse Events of Baricitinib Treatment for Coronavirus Disease-2019 (COVID-19): A Systematic Review and Meta-Analysis